Signadori Bio is the next-generation cellular immunotherapy for cancer cure.
Signadori Bio has raised $13.0M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Signadori Bio's investors include Taiho Ventures, Sofinnova Partners, Invivo Capital Partners.
Signadori Bio is headquartered in Paris, France.
Signadori Bio is the next-generation cellular immunotherapy for cancer cure.
Signadori Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Signadori Bio — Funding & Investors." VCBacked, May 6, 2026, https://www.vcbacked.co/company/signadori-bio. Accessed October 1, 2026.
VCBacked. (2026). Signadori Bio — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/signadori-bio
{{cite web |title=Signadori Bio — Funding & Investors |url=https://www.vcbacked.co/company/signadori-bio |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated